Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Cash Return on Equity (CROE) for the quarter ending March 31, 2024: -0.31

Allakos Inc Cash Return on Equity (CROE) is -0.31 for the quarter ending March 31, 2024, a -191.20% change year over year. The cash return on equity ratio measures the profitability of a company's shareholders' equity based on its operating cash flow. It is calculated by dividing operating cash flow by shareholders' equity. This ratio provides insight into how effectively the company generates cash flow in relation to the shareholders' investment. A higher ratio indicates better cash flow generation relative to the equity invested.

Allakos Inc Cash Return on Equity (CROE) for the quarter ending March 31, 2023 was -0.11, a 83.98% change year over year.
Allakos Inc Cash Return on Equity (CROE) for the quarter ending March 31, 2022 was -0.67, a -793.14% change year over year.
Allakos Inc Cash Return on Equity (CROE) for the quarter ending March 31, 2021 was -0.08, a -92.84% change year over year.
Allakos Inc Cash Return on Equity (CROE) for the quarter ending March 31, 2020 was -0.04, a 50.77% change year over year.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends